Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | DHODH | Q02127 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 5/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19168246 | 1.00 | HSD17B10 (0.45) | HSD17B10MAPK1TSHRDHODHHPGD | |
| SCHEMBL19166391 | 0.95 | HSD17B10 (0.45) | HSD17B10MAPK1TSHRDHODHHPGD | |
| SCHEMBL19168247 | 0.95 | HSD17B10 (0.45) | HSD17B10MAPK1TSHRDHODHHPGD | |
| SCHEMBL19167773 | 0.95 | HSD17B10 (0.45) | HSD17B10MAPK1TSHRDHODHHPGD | |
| SCHEMBL19167466 | 0.92 | HSD17B10 (0.50) | HSD17B10MAPK1TSHRDHODHHPGD | |
| SCHEMBL19168467 | 0.90 | SMN1; SMN2 (0.41) | HSD17B10MAPK1TSHRDHODHHPGD | |
| SCHEMBL12210854 | 0.88 | ALDH1A1 (0.50) | HSD17B10MAPK1TSHRDHODHHPGD | |
| SCHEMBL16407280 | 0.86 | HSD17B10 (0.40) | HSD17B10MAPK1TSHRDHODHHPGD | |
| SCHEMBL19167359 | 0.86 | MAPT (0.42) | HSD17B10MAPK1TSHRDHODHHPGD | |
| SCHEMBL19166280 | 0.86 | MAPT (0.42) | HSD17B10MAPK1TSHRDHODHHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10797244-B2 | Compound, material for organic electroluminescent element, organic electroluminescent element, and electronic device | IDEMITSU KOSAN CO., LTD. (JP) | 2020-10-06 | — | — | US | disclosed |
| US-20170213982-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2017-07-27 | — | — | US | disclosed |
| US-20170213982-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10797244-B2 | Compound, material for organic electroluminescent element, organic electroluminescent element, and electronic device | RER1, RBM12, H1-2 | HSD17B10 2839/4885MAPK1 500/4885TSHR 1590/4885 |
| US-20170213982-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | RER1, RBM12, H1-2 | HSD17B10 2839/4885MAPK1 500/4885TSHR 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.